| Mrs Amanda Austa Goodrich, MA, LMHC | |
|
123 N Linn St, Suite 2a, Iowa City, IA 52245-2143 | |
| (319) 337-3357 | |
| (319) 337-2758 |
| Full Name | Mrs Amanda Austa Goodrich |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 123 N Linn St, Iowa City, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033447842 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 00955 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Amanda Austa Goodrich, MA, LMHC 123 N Linn St, Suite 2a, Iowa City, IA 52245-2143 Ph: (319) 337-3357 | Mrs Amanda Austa Goodrich, MA, LMHC 123 N Linn St, Suite 2a, Iowa City, IA 52245-2143 Ph: (319) 337-3357 |
News Archive
The University of Tokyo entered an agreement for developing a personalized cancer vaccine using a novel method involving the body's immune response.
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria on Thursday announced it will "integrate" the Affordable Medicines Facility-malaria (AMFm), implemented in 2010 as a pilot program to provide low-cost artemisinin-based combination therapies (ACTs) in poor and rural areas, "into its existing core system of providing grants to countries to purchase drugs, bed nets and other malaria-control measures," Nature News Blog reports.
Celsion Corporation, a leading oncology drug development company, announced that after reviewing data from 401 patients enrolled in its pivotal Phase III ThermoDox ® clinical study (the HEAT study) for primary liver cancer, the Data Monitoring Committee (DMC) has unanimously recommended that the trial continue to enroll patients with the goal of reaching the 600 patients required to complete the study.
Researchers at Karolinska Institutet in Sweden have identified a new so-called pseudogene that regulates the tumour-suppressing PTEN gene. They hope that this pseudogene will be able to control PTEN to reverse the tumour process, make the cancer tumour more sensitive to chemotherapy and to prevent the development of resistance.
Top Performing Drug Developers Are Merging Operational And Strategic Objectives, According To Tufts Center For The Study Of Drug Development
› Verified 5 days ago
Christopher M Loeckle, LISW Counselor Medicare: Not Enrolled in Medicare Practice Location: 221 E College St Ste 211, Iowa City, IA 52240 Phone: 319-541-5859 | |
Christine Marie Vincent, LISW Counselor Medicare: Accepting Medicare Assignments Practice Location: 757 W Benton St, Iowa City, IA 52246 Phone: 319-339-4757 | |
Vicki Lynn Osland, LMSW, CADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 200 Hawkins Dr, C124 Gh, Iowa City, IA 52242 Phone: 319-356-8935 Fax: 319-384-9362 | |
Dr. M Kay Colangelo, PH.D. Counselor Medicare: Not Enrolled in Medicare Practice Location: 123 N Linn St, Suite 2-d, Iowa City, IA 52245 Phone: 319-337-9461 | |
Mark Biangmano, T-LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 332 S Linn St Ste 40, Iowa City, IA 52240 Phone: 319-894-5069 | |
Bria Sarah Kates, TLMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 509 Kirkwood Ave, Iowa City, IA 52240 Phone: 319-519-2147 |